CELLECTIS NOM. EO-,05CELLECTIS NOM. EO-,05CELLECTIS NOM. EO-,05

CELLECTIS NOM. EO-,05

No trades
See on Supercharts
Next report date
Report period
Q1 2024
EPS estimate
−0.30EUR
Revenue estimate
‪3.45 M‬EUR
Market capitalization
‪174.71 M‬EUR
−1.605EUR
‪−93.48 M‬EUR
‪698.35 K‬EUR
‪43.14 M‬
Beta (1Y)
5.47

About CELLECTIS

CEO
André Choulika
Headquarters
Paris
Founded
1999
ISIN
FR0010425595
FIGI
BBG000BFWPZ4
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange CELLECTIS NOM. EO-,05 stocks are traded under the ticker ZVA.
CELLECTIS NOM. EO-,05 is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
ZVA earnings for the last quarter are −0.29 EUR per share, whereas the estimation was −0.39 EUR resulting in a 25.66% surprise. The estimated earnings for the next quarter are −0.18 EUR per share. See more details about CELLECTIS NOM. EO-,05 earnings.
CELLECTIS NOM. EO-,05 revenue for the last quarter amounts to ‪1.54 M‬ EUR despite the estimated figure of ‪3.34 M‬ EUR. In the next quarter revenue is expected to reach ‪1.66 M‬ EUR.
Yes, you can track CELLECTIS NOM. EO-,05 financials in yearly and quarterly reports right on TradingView.
ZVA net income for the last quarter is ‪−39.86 M‬ EUR, while the quarter before that showed ‪−16.07 M‬ EUR of net income which accounts for −148.01% change. Track more CELLECTIS NOM. EO-,05 financial stats to get the full picture.
No, ZVA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ZVA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CELLECTIS NOM. EO-,05 stock right from TradingView charts — choose your broker and connect to your account.
ZVA reached its all-time high on Nov 6, 2015 with the price of 41.750 EUR, and its all-time low was 0.875 EUR and was reached on Oct 30, 2023. View more price dynamics on ZVA chart.
See other stocks reaching their highest and lowest prices.
We've gathered analysts' opinions on CELLECTIS NOM. EO-,05 future price: according to them, ZVA price has a max estimate of 9.35 EUR and a min estimate of 2.81 EUR. Watch ZVA chart and read a more detailed CELLECTIS NOM. EO-,05 stock forecast: see what analysts think of CELLECTIS NOM. EO-,05 and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CELLECTIS NOM. EO-,05 EBITDA is ‪−82.29 M‬ EUR, and current EBITDA margin is ‪−11.67 K‬%. See more stats in CELLECTIS NOM. EO-,05 financial statements.